Balyasny Asset Management
APLT

Balyasny Asset Management’s Applied Therapeutics APLT Stock Holding History

Balyasny Asset Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,605
Closed -$35.5K – 2593
2023
Q4 		$35.5K Buy
+10,605
New +$26.4K ﹤0.01% 2414

Other funds holding APLT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Balyasny Asset Management's APLT Position: Q1 2024 in Review

Balyasny Asset Management sold out of Applied Therapeutics (APLT) in Q1 2024, closing a stake of 10,605 shares — an estimated $35.5K sold.

Balyasny Asset Management first reported a position in APLT in Q4 2023 and held it in 1 quarter. The position peaked at $35.5K in Q4 2023. 89 funds tracked by Wall St. Rank hold APLT as of Q1 2024.

  • Balyasny Asset Management reported no remaining Applied Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 10,605 Applied Therapeutics shares in Q1 2024, an estimated $35.5K.
  • Balyasny Asset Management first reported a position in Applied Therapeutics in Q4 2023 and held it in 1 quarter.
  • Balyasny Asset Management's Applied Therapeutics position peaked at $35.5K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.